Articles on Aesthetics Academy

If something goes wrong after a cosmetic injection in the UK

Tue, 11 Aug 2026 00:00:00 +0000

There are two different situations that get discussed together and should not be. One is a medical emergency measured in minutes. The other is a complaint, measured in weeks. Doing the second when you needed the first is how bad outcomes become permanent ones.

Emergency first

Some findings after an injection are not “wait and see” problems.

Vision change of any kind — blurring, a dark area, loss on one side.
Severe pain out of proportion, or unusual pain that keeps increasing.
Blanching: skin going white in a pattern that spreads beyond the injection point, later turning dusky, mottled or net-like.
Neurological symptoms — weakness on one side, slurred speech, facial droop that is not simple numbness.

These suggest that material has entered a blood vessel. Published case series show that once the retinal circulation is involved the window before loss becomes irreversible is roughly 60 to 90 minutes.

Which UK register to check, and what it tells you

Fri, 07 Aug 2026 00:00:00 +0000

Checking a practitioner takes a few minutes and is free. The difficulty is not access — it is knowing which register applies and what an entry does and does not prove.

The statutory registers

These are held by bodies with legal powers. They can impose conditions, suspend and remove. An entry can be checked by anyone, and each shows more than a yes or no.

Doctors — the General Medical Council. The register confirms current registration, whether the doctor holds a licence to practise, and whether any restrictions apply. The licence matters: registration without a licence does not permit prescribing.

Choosing an aesthetic practitioner in the UK

Tue, 04 Aug 2026 00:00:00 +0000

Most people assume that anyone injecting faces for money must be qualified and licensed to do it, in the way a driving instructor or an electrician is. In England that assumption is, as things stand, wrong — and understanding why is the single most useful thing a prospective patient can know.

What the law currently requires

Two things are settled.

Under-18s. It is an offence to administer botulinum toxin or a cosmetic filler to someone under 18 for cosmetic purposes in England, under the Botulinum Toxin and Cosmetic Fillers (Children) Act 2021, with a narrow exemption for a regulated healthcare professional acting in a clinical capacity.

Skin boosters: injectable hydration versus volume

Thu, 30 Jul 2026 00:00:00 +0000

“Skin booster” describes an intent rather than a molecule. The material is usually hyaluronic acid — the same substance as in dermal filler — but formulated, placed and expected to behave completely differently.

The distinction

A dermal filler is designed to occupy space and resist deformation. It is crosslinked densely enough to hold shape against the tissue pressing on it, and placed deep enough that its structure is not visible through the skin.

Dermal filler aftercare: what matters and what does not

Mon, 27 Jul 2026 00:00:00 +0000

“Dermal filler aftercare” is a rising search, and most of what it returns is a list of prohibitions with no reasoning attached. The reasoning is the useful part, because it separates advice that matters from advice that is repeated out of habit.

What is expected

Mild swelling, redness, tenderness and small bruises at injection sites are ordinary post-injection reactions. Regulatory safety information lists bruising, swelling, erythema, pain, tenderness and itching among the common reactions, most resolving over days to weeks.

Calcium hydroxylapatite (Radiesse): how it stimulates collagen

Thu, 23 Jul 2026 00:00:00 +0000

Calcium hydroxylapatite sits awkwardly between categories. It fills like a filler and stimulates like a biostimulator, and understanding both halves is the only way to use it sensibly — or to understand why it behaves differently from hyaluronic acid.

Composition

The product is a suspension: calcium hydroxylapatite microspheres, described in the literature as roughly 30% of the volume at 25–45 μm diameter, carried in a carboxymethyl cellulose gel making up the remaining 70%.

Polynucleotides and PDRN: what the evidence actually shows

Mon, 20 Jul 2026 00:00:00 +0000

Polynucleotides are the fastest-growing search category in UK aesthetics, and the questions being asked — what they are, whether they work, how they differ from filler — suggest the marketing has run ahead of the explanation.

What they are

Polynucleotides (PN) and polydeoxyribonucleotides (PDRN) are fragments of DNA. Both are conventionally derived from the sperm cells of salmon or trout, purified to remove protein and leave the nucleotide chains themselves.

Myomodulation with dermal filler: what the concept claims

Sun, 05 Jul 2026 00:00:00 +0000

Myomodulation proposes that filler can change facial dynamics — altering how muscles act — rather than only adding static volume. It has become influential in contemporary teaching, and it is worth understanding both what it claims and how firm the ground under it is.

The mechanical argument

A muscle acts between an origin and an insertion. Facial muscles typically originate on bone and insert into soft tissue or into other muscles.

Advertising Botox in the UK: what the rules actually say

Mon, 29 Jun 2026 00:00:00 +0000

In the United Kingdom, botulinum toxin — marketed as Botox, Vistabel, Dysport and others — is a prescription-only medicine. The consequence for anyone promoting treatment is direct and frequently misunderstood: it cannot be advertised to the public at all.

The two instruments

CAP Code rule 12.12 states that prescription-only medicines or treatments may not be advertised to the public. This governs marketing communications and is enforced by the Advertising Standards Authority.

Lifting versus volumising: two different corrections

Fri, 26 Jun 2026 00:00:00 +0000

“Lifting” and “volumising” are used interchangeably in consultation and mean quite different things mechanically. Confusing them is one of the more common reasons a technically clean treatment produces a disappointing face.

Volumising

Replacing what has been lost. Fat compartments deflate and bone resorbs; volumising restores the missing bulk in the compartment where it went missing.

The requirement is a product that integrates and fills — moderate G′, good cohesivity — placed within the compartment concerned. The endpoint is restoration of a contour that used to exist.

Facial anatomy in layers: what lies beneath the skin

Sat, 20 Jun 2026 00:00:00 +0000

The face is conventionally described as five concentric layers, consistent from scalp to neck in their order if not in their thickness. From the surface: skin, subcutaneous fat, the musculoaponeurotic layer (SMAS and the mimetic muscles invested within it), deep fat and areolar tissue, and the deep fascia and periosteum overlying bone. Every injectable decision is, in effect, a decision about which of these five to enter and where to stop.

Filler migration: does filler stay where you put it?

Wed, 17 Jun 2026 00:00:00 +0000

The assumption behind every treatment plan is that product stays where it is put. It usually does. When it does not, the reasons are mechanical and largely predictable.

Placement versus migration

Two different things get called migration.

Immediate displacement is product moving during or shortly after injection — pushed along a tissue plane by injection pressure, by massage, or by muscle activity before it has integrated. This is a placement problem.

Structural lifting technique: fixed points and anchors

Thu, 11 Jun 2026 00:00:00 +0000

“Lifting” with injectable filler is a mechanical claim, and it is worth stating the mechanics plainly rather than treating the word as a marketing synonym for filling. Nothing is pulled upwards. What happens is that material placed in a load-bearing plane alters the geometry of the tissues resting on it, and the soft tissue attached to that framework changes position as a consequence.

The two planes

The anatomical literature distinguishes a deep, load-bearing compartment from a superficial, shape-modulating one. The deep plane — supraperiosteal, or within the deep fat compartments — is where structural support is generated and where positional change originates. The superficial plane determines contour and surface quality but carries no load; material placed there follows the tissue rather than moving it.

Botulinum toxin pharmacology, units and handling

Fri, 05 Jun 2026 00:00:00 +0000

Botulinum neurotoxin is a bacterial protein produced by Clostridium botulinum. Seven principal serotypes are described, labelled A to G, distinguished by their antigenicity and by which component of the SNARE complex they cleave. Cosmetic and most therapeutic practice uses serotype A; serotype B has a smaller therapeutic role. The remainder are of laboratory rather than clinical interest, but their differences are informative because they explain why duration of effect varies.

High-dose pulsed hyaluronidase protocol explained

Tue, 02 Jun 2026 00:00:00 +0000

The high-dose pulsed protocol is the standard published approach to hyaluronic acid vascular occlusion, and it differs from elective dissolution in almost every parameter.

The reasoning

An occluding plug of filler sits inside a vessel. To be dissolved it must be reached by enzyme, and the enzyme has to be present in sufficient concentration for long enough. A single injection produces a brief peak that decays quickly — often before the plug has been meaningfully degraded.

Botox foundation handbook: the three licensed areas

Wed, 27 May 2026 00:00:00 +0000

Foundation-level cosmetic use of botulinum toxin type A concerns three areas of the upper face covered by marketing authorisation: the glabellar complex, the lateral canthal lines and the frontalis. The anatomy of these three regions accounts for most of what a foundation reference needs to cover, because almost every predictable adverse outcome in the upper face is a consequence of a muscle being treated that was not the intended target.

How hyaluronidase breaks down hyaluronic acid filler

Sun, 24 May 2026 00:00:00 +0000

Hyaluronidase depolymerises hyaluronic acid by cleaving the glycosidic bonds in the chain. That single sentence covers the mechanism; almost everything clinically interesting is in the qualifications.

Crosslinking changes the target

Native hyaluronic acid is a long unbranched chain, cleared from tissue within a day or two. Filler hyaluronic acid is crosslinked — chains tied together into a three-dimensional network — which is what gives it persistence and mechanical behaviour.

The enzyme still cleaves the chains, but a densely crosslinked network presents fewer accessible sites and holds together after partial cleavage. The practical consequence is that products differ in how readily they dissolve: a soft, lightly crosslinked gel yields quickly, while a dense, highly crosslinked structural product may need repeated treatment.

Ischaemic stroke after facial filler injection

Mon, 18 May 2026 00:00:00 +0000

Cerebral infarction after cosmetic filler injection is rare. It is also documented well enough in the case literature that it belongs in any honest account of injectable risk.

The route

The mechanism extends the one behind filler-induced blindness. Material entering a facial artery branch under pressure travels retrograde toward the anastomoses around the orbit. From the ophthalmic artery it can reach the internal carotid circulation and, from there, intracranial branches — the middle cerebral artery territory in particular.

Tear trough assessment before technique

Fri, 15 May 2026 00:00:00 +0000

The infraorbital hollow is the most requested and least forgiving treatment on the face. Most poor outcomes there are assessment failures rather than technical ones.

The anatomy that makes it difficult

The tear trough marks the tear trough ligament, an osteocutaneous attachment from maxilla to dermis. Above it the skin is the thinnest on the body, with almost no subcutaneous fat and orbicularis oculi directly beneath. Below sits the medial cheek fat.

Cannula versus needle: vessel penetration risk

Tue, 12 May 2026 00:00:00 +0000

The cannula-versus-needle question has better data behind it than most technique debates in aesthetic medicine, and the direction of the finding is consistent.

What the comparison shows

Analyses of large injection series report cannula use associated with substantially lower odds of vascular occlusion — on the order of a 77% reduction, corresponding in one dataset to roughly one occlusion per 40,882 cannula injections against one per 6,410 needle injections. Reviews across the literature put the odds reduction somewhere in the 50–80% range depending on the analysis.

Dilution of hyaluronidase: concentration and purpose

Wed, 06 May 2026 00:00:00 +0000

Hyaluronidase is supplied as a lyophilised powder and must be reconstituted before use. The choice of diluent volume is not a detail of preparation: it determines both the concentration of enzyme delivered and the volume of tissue that can be reached, and those two variables serve different purposes in different clinical situations.

Two variables, two purposes

Reconstituting a 1500-unit vial into a small volume produces a concentrated solution suitable for delivering enzyme activity to a defined target. Reconstituting the same vial into a larger volume produces a dilute solution that distributes further through tissue for the same total dose. Total units and volume are independent choices, and confusing them is the most common error in discussions of hyaluronidase dosing.

Blindness after filler: visual loss and the 90-minute window

Sun, 03 May 2026 00:00:00 +0000

Vision loss after cosmetic filler is rare, has been reported from Asia, Europe and North America, and is in most published cases irreversible. It is the complication that shapes how careful practice is organised.

Mechanism

The eye is supplied by the ophthalmic artery, a branch of the internal carotid. The face is supplied largely by the facial artery, a branch of the external carotid. The two systems anastomose, most importantly where the angular artery meets the dorsal nasal branch at the medial canthus.

Facial topography: reading the face in light and shadow

Thu, 30 Apr 2026 00:00:00 +0000

Patients describe faces in terms of lines and hollows. What they are actually responding to is topography — the pattern of light and shadow produced by a three-dimensional surface — and learning to read that pattern is more useful than cataloguing individual wrinkles.

Lights and shadows

A convex surface catches light; a concave one falls into shadow. A young face has a characteristic arrangement: highlights over the forehead, the malar eminence, the tip of the nose, the chin and the cupid’s bow; soft transitions between them.

Filler rheology made simple: G prime and cohesivity

Mon, 27 Apr 2026 00:00:00 +0000

Filler rheology is often presented as a table of numbers with no obvious connection to clinical choice. The numbers do mean something, but only two questions matter: how does this gel move through a needle, and how does it behave once it has stopped moving.

G′ — elastic modulus

G′ (G prime) is the storage modulus: resistance to deformation under shear. It is the most commonly used parameter to distinguish products, and higher values track with higher hyaluronic acid concentration and molecular weight.

Skin necrosis after filler: recognition and avoidance

Tue, 21 Apr 2026 00:00:00 +0000

Skin necrosis after filler is the visible end of a process that started, silently, at the moment of injection. Understanding the sequence is what makes early intervention possible.

The sequence

Filler enters an artery. It travels — forward with flow, or retrograde if injection pressure exceeds arterial pressure — and lodges where the vessel narrows. Downstream tissue loses its supply. If collateral circulation is adequate, nothing happens. If it is not, the tissue becomes ischaemic, then infarcts.

Retaining ligaments of the face and why folds form

Wed, 15 Apr 2026 00:00:00 +0000

Faces do not sag uniformly. They fold at specific, reproducible lines, and the reason is a set of fibrous structures that tether soft tissue to the skeleton.

The named structures

The zygomatic ligament anchors over the malar eminence. The mandibular ligament attaches near the parasymphyseal mandible. The masseteric ligaments run along the anterior border of masseter. The orbital retaining ligament encircles the orbital rim, and the tear trough ligament runs from maxilla to dermis inferomedially from the canthus.

Marketing an aesthetic practice under UK advertising law

Sun, 12 Apr 2026 00:00:00 +0000

Digital marketing guidance written for general small businesses does not transfer to aesthetic practice in the United Kingdom, because one of the products involved is a prescription-only medicine and prescription-only medicines cannot lawfully be advertised to the public. This is the single rule that most frequently catches new practices, and it is not a matter of tone or taste. It is a statutory prohibition with a separate advertising code sitting on top of it.

Nerve supply to the face: trigeminal and facial nerves

Thu, 09 Apr 2026 00:00:00 +0000

Two separate nerve systems serve the face, and keeping them apart is the difference between correctly interpreting a post-treatment problem and guessing.

Sensation: trigeminal (V)

V1, ophthalmic — forehead, upper eyelid, nasal dorsum, cornea. Exits at the supraorbital and supratrochlear notches.

V2, maxillary — lower eyelid, cheek, lateral nose, upper lip. Exits at the infraorbital foramen, about a centimetre below the inferior orbital rim.

V3, mandibular — lower lip, chin, jaw; motor to the muscles of mastication. Exits at the mental foramen between the premolars.

Avoiding hyaluronic acid complications: a ten-point plan

Fri, 03 Apr 2026 00:00:00 +0000

No single precaution prevents a vascular event. What the complication literature describes is a stack of measures, each removing part of the risk, and the practitioners who get into trouble are usually missing several at once rather than one.

1. Know the regional anatomy before the needle is in your hand

Not facial anatomy in general — the specific vessels of the specific region, their usual course, and how much they vary. Published danger-zone mapping exists precisely so this does not have to be reconstructed from memory mid-treatment.

Lower face injection anatomy: jawline, chin, perioral

Sat, 28 Mar 2026 00:00:00 +0000

The lower third combines a dense arterial supply with constant functional demand. Errors here are visible in conversation, not just in photographs.

Muscles

Orbicularis oris forms the sphincter of the mouth. Into it insert the elevators — levator labii superioris, zygomaticus major and minor — and the depressors: depressor anguli oris (DAO), depressor labii inferioris, mentalis.

Each participates in speech and eating, so weakening any of them has functional consequences. The DAO is a common toxin target for a downturned mouth corner, but it sits directly adjacent to the depressor labii inferioris; diffusion between them produces an asymmetric smile that lasts months.

Midface injection anatomy: compartments and ligaments

Wed, 25 Mar 2026 00:00:00 +0000

The midface is where most volumising work happens, and where the difference between filling a shadow and correcting its cause is most consequential.

Layers and compartments

The midface is layered: skin, subcutaneous fat, SMAS, deep fat, deep fascia, periosteum. The fat is not a sheet but a set of discrete compartments — superficial and deep, medial and lateral — separated by septa and tethered by ligaments.

Anatomical study of the subSMAS spaces shows these are bordered by fat, muscle, fascia and ligaments, permitting independent muscle movement and offering planes that are separated from critical neurovascular structures. That is the anatomical basis for the idea of a safe plane: not an absence of vessels, but a fascial or muscular layer between the injected material and them.

Upper face injection anatomy: forehead, glabella, temple

Sun, 22 Mar 2026 00:00:00 +0000

The upper face is the paradox of injectable practice. For botulinum toxin it is the most predictable region on the face. For filler it is among the most dangerous.

Muscles

Frontalis elevates the brow. It is the sole elevator, which is the fact that governs everything about treating it. Corrugator supercilii draws the brows medially and downward. Procerus pulls the medial brow down. Orbicularis oculi closes the eye; its lateral fibres produce crow’s feet.

Biostimulation: what collagen-stimulating injectables do

Thu, 19 Mar 2026 00:00:00 +0000

“Biostimulation” is a category label rather than a product description. It covers injectables whose intended effect is mediated by the tissue response to the material rather than by the material’s own bulk: poly-L-lactic acid, calcium hydroxylapatite, polycaprolactone, and a looser group of nutrient, amino acid and polynucleotide preparations sometimes marketed under skin-quality or “nutrient lift” headings. The label groups together products with genuinely different mechanisms and very different evidence bases, which is the first thing to notice about it.

Jean Carruthers and the origins of cosmetic Botox

Tue, 10 Mar 2026 00:00:00 +0000

Almost every account of aesthetic medicine’s modern history passes through the same observation, made by a patient rather than a researcher, in a Vancouver ophthalmology clinic in the late 1980s.

This page is a reference note on that history. It has no connection to Dr Carruthers, who has never been associated with this site.

Who she is

Dr Jean Carruthers is a clinical professor in the Department of Ophthalmology and Visual Sciences at the University of British Columbia in Vancouver. She took her medical degree at UBC in 1971 and completed ophthalmology training at the Institute of Ophthalmology and Moorfields Eye Hospital in London, finishing in 1977. Her clinical field is oculoplastic surgery — the surgery of the eyelids, orbit and tear system.

Advanced botulinum toxin: a structured reading outline

Sat, 07 Mar 2026 00:00:00 +0000

This page is a reading outline rather than a course. It sets out the questions that recur across the advanced toxin literature, organised so that a practitioner can test their own coverage of a region before reading further. Nothing here is a protocol, and no dose figures are given; the point of the exercise is to identify the gaps that reading has to close.

Before any advanced area

Four questions apply to every region outside the licensed upper face.

Advanced botulinum toxin: beyond the licensed upper face

Sun, 01 Mar 2026 00:00:00 +0000

The licensed cosmetic indications for botulinum toxin type A in the United Kingdom cover a narrow band of the face: the glabellar complex, the lateral canthal lines and the frontalis. Everything else that is routinely described in the aesthetic literature — the nasal tip, the gummy smile, the depressor anguli oris, the mentalis, the platysma, the masseter — sits outside those marketing authorisations. That is what “advanced” means in practice. It is not a statement about difficulty; it is a statement about regulatory status.

Blood supply to the face: facial artery anatomy

Mon, 23 Feb 2026 00:00:00 +0000

Facial vascular anatomy matters in aesthetic practice for one blunt reason: the arteries of the face are not a closed system. The external carotid supply and the internal carotid supply meet, and material introduced into a branch of one can reach territory belonging to the other. The serious injectable complications described in the literature follow from that single anatomical fact.

The two supplies

The face is served principally by the facial artery, a branch of the external carotid. It crosses the mandible at the anterior border of the masseter, runs a tortuous course toward the nose, and continues as the angular artery alongside the nasal sidewall toward the medial canthus.